---

Tofacitinib: A paradigm shift in rheumatoid arthritis management

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Ashok Ramanujam, Janakapriya Ashok*

Volume : 10, Issue : 1, Year : 2024

Article Page : 3-7

https://doi.org/10.18231/j.ijor.2024.002

Suggest article by email

Get Permission

Abstract

Tofacitinib, a Janus kinase (JAK) inhibitor, represents a significant advancement in the treatment of rheumatoid arthritis (RA), a chronic inflammatory disorder. This manuscript provides an in-depth review of the efficacy, safety, and clinical application of tofacitinib in RA management. Through a comprehensive analysis of clinical trials, real-world studies, and comparative assessments with other RA therapies, we aim to elucidate the role of tofacitinib in improving patient outcomes. The review highlights the mechanisms of action, clinical efficacy, safety profile, and practical considerations for incorporating tofacitinib into RA treatment regimens.
 

Keywords: Tofacitinib, Rheumatoid Arthritis, JAK Inhibitors, Inflammatory Disorders, Clinical Trials, Patient Outcomes, Treatment Management

How to cite : Ramanujam A, Ashok J, Tofacitinib: A paradigm shift in rheumatoid arthritis management. IP Int J Orthop Rheumatol 2024;10(1):3-7

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.